CY1105140T1 - Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα - Google Patents

Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα

Info

Publication number
CY1105140T1
CY1105140T1 CY20061100997T CY061100997T CY1105140T1 CY 1105140 T1 CY1105140 T1 CY 1105140T1 CY 20061100997 T CY20061100997 T CY 20061100997T CY 061100997 T CY061100997 T CY 061100997T CY 1105140 T1 CY1105140 T1 CY 1105140T1
Authority
CY
Cyprus
Prior art keywords
group
diseases
disease
nitrogen atom
contained
Prior art date
Application number
CY20061100997T
Other languages
English (en)
Inventor
Alexander Ernst
Andreas Huth
Martin Kruger
Karl-Heinz Thierauch
Andreas Menrad
Martin Haberey
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001123587 external-priority patent/DE10123587B4/de
Priority claimed from DE2001125295 external-priority patent/DE10125295A1/de
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of CY1105140T1 publication Critical patent/CY1105140T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)

Abstract

Περιγράφονται υποκατεστημένα παράγωγα κυανοανθρανυλαμιδίου, η παραγωγή και η χρήση αυτών ως φαρμακευτικά μέσα για την αντιμετώπιση παθήσεων, οι οποίες προκαλούνται από επίμονη αγγειογένεση. Οι σύμφωνες με την εφεύρεση ενώσεις δύνανται να χρησιμοποιηθούν στην ψωρίαση, σάρκωμα Kaposi, επαναστένωση, όπως π.χ. επαναστένωση προκαλούμενη από Stent, ενδομητρίωση, νόσο του Crohn, νόσο του Hodgkin, λευχαιμία, αρθρίτιδα, όπως ρευματοειδή αρθρίτιδα, αιμαγγείωμα, αγγειοΐνωμα, οφθαλμικές παθήσεις, όπως διαβητική αμφιβληστροειδοπάθεια, νεοαγγειακό γλαύκωμα, νεφρικές παθήσεις, όπως σπειραματονεφρίτιδα, διαβητική νεφροπάθεια, κακοήθη νεφροσκλήρυνση, θρομβωτικό μικροαγγειοπαθικό σύνδρομο, απόρριψη μοσχεύματος και σπειραματοπάθεια, ινωτικές παθήσεις, όπως κίρρωση ήπατος, πολλαπλασιαστικές παθήσεις μεσαγγειακών κυττάρων, αρτηριοσκλήρυνση, τραυματισμούς του νευρικού ιστού και αναστολή της επαναπόφραξης των αγγείων μετά από θεραπεία με καθετήρα μπαλονιού, στην αγγειοπροσθετική ή μετά την τοποθέτηση μηχανικών διατάξεων για τη διατήρηση των αγγείων ανοικτών, όπως π.χ. Stents, ως ανοσοκατασταλτικά, ως υποστήριξη στην επούλωση πληγών άνευ ουλής, κηλίδες λόγω ηλικίας και δερματίτιδα επαφής. Οι σύμφωνες με την εφεύρεση ενώσεις δύνανται επίσης να χρησιμοποιηθούν ως αναστολείς του VEGFR-3 στη λεμφαγγειογένεση. Ενώσεις του γενετικού τύπου (I), στον οποίο Α σημαίνει την ομάδα -N(R7)-, Υ1 έως Υ5 σημαίνουν εκάστοτε άτομο αζώτου ή την ομάδα -CY5, Υ6 σημαίνει κυανό ομάδα, αλογόνο, C1-C6-αλκύλιο, C1-C6- αλκοξυ ομάδα, αμινο ομάδα ή υδροξυ ομάδα, όπου εντός του δακτυλίου περιέχεται τουλάχιστον ένα άτομο αζώτου και επί το δακτυλίου περιέχεται τουλάχιστον μία κυανό ρίζα.
CY20061100997T 2001-05-08 2006-07-18 Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα CY1105140T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001123587 DE10123587B4 (de) 2001-05-08 2001-05-08 Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE2001125295 DE10125295A1 (de) 2001-05-15 2001-05-15 Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II)
PCT/EP2002/004921 WO2003000678A1 (de) 2001-05-08 2002-05-03 Cyanoanthranylamid-derivate und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
CY1105140T1 true CY1105140T1 (el) 2010-03-03

Family

ID=26009296

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100997T CY1105140T1 (el) 2001-05-08 2006-07-18 Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα

Country Status (13)

Country Link
US (1) US7429592B2 (el)
EP (1) EP1387838B1 (el)
JP (1) JP4343681B2 (el)
AR (1) AR035879A1 (el)
AT (1) ATE323694T1 (el)
CY (1) CY1105140T1 (el)
DE (1) DE50206476D1 (el)
DK (1) DK1387838T3 (el)
ES (1) ES2261693T3 (el)
PE (1) PE20030037A1 (el)
PT (1) PT1387838E (el)
TW (1) TWI251593B (el)
WO (1) WO2003000678A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE50213703D1 (de) * 2001-05-08 2009-09-03 Bayer Schering Pharma Ag Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655297A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US20110142839A1 (en) * 2008-05-30 2011-06-16 Vegenics Limited Treatment of pulmonary edema
KR20110045095A (ko) 2008-08-27 2011-05-03 레오 파마 에이/에스 Ｖｅｇｆｒ-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체
EP2957283B1 (de) 2014-06-19 2022-12-21 Symrise AG Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
CN112675173B (zh) * 2020-12-25 2022-04-05 华南理工大学 FXIa抑制剂化合物或其盐的医药用途
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6910994A (en) 1993-05-14 1994-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE19910396C2 (de) 1999-03-03 2001-12-13 Schering Ag Anthranilsäureamide und deren Verwendung als Arzneimittel
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use

Also Published As

Publication number Publication date
ES2261693T3 (es) 2006-11-16
PT1387838E (pt) 2006-08-31
WO2003000678A1 (de) 2003-01-03
US7429592B2 (en) 2008-09-30
JP2004532281A (ja) 2004-10-21
EP1387838A1 (de) 2004-02-11
JP4343681B2 (ja) 2009-10-14
DE50206476D1 (de) 2006-05-24
ATE323694T1 (de) 2006-05-15
US20040266770A1 (en) 2004-12-30
TWI251593B (en) 2006-03-21
EP1387838B1 (de) 2006-04-19
AR035879A1 (es) 2004-07-21
DK1387838T3 (da) 2006-08-14
PE20030037A1 (es) 2003-02-05

Similar Documents

Publication Publication Date Title
CY1105140T1 (el) Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα
MXPA03010099A (es) Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.
BR0313122A (pt) Antranilamidopiridinas inibidoras de vegfr-2 e vegfr-3
AU2005247808B2 (en) Quinazoline derivative
MY130780A (en) 2,4,5-trisubstituted thiazolyl derivatives
RU2001128067A (ru) Производные амида
NO20020421L (no) Tricykliske inhibitorer av poly(ADP-ribose)-polymeraser
ATE485275T1 (de) Nicotinamide und deren verwendung als p38 inhibitoren
CA2491895A1 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
RU2007120692A (ru) Новые антраниламидопиридинмочевины в качестве ингибитов киназы рецептора vegf
AU5513996A (en) 1,4-di-substituted piperidine derivatives
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
JP2019505595A5 (el)
AR035877A1 (es) Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen
ES2183839T3 (es) Composiciones y procedimiento de reparacion y de prevencion de lesiones del tipo de fibrosis.
HUP0301954A2 (hu) Orto-szubsztituált antranilsav-amidok és felhasználásuk gyógyszerként
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
NO305864B1 (no) Alkoksyalkylkarbamater av imidazo (1,2-a)pyridiner
MXPA04000917A (es) 2-(3, 5-bis-trifluorometil -fenil)-n -[6-(1, 1-dioxo-1lambda 6-tio- morfolin- 4-il)- 4-(2-metil o 4-fluor- 2-metil substituido)fenil -piridin- 3-il]-n -metil-isobutiramida.
ATE169917T1 (de) Imidazo (4,5-c)pyridinderivate als paf antagonisten
HU911352D0 (en) Process for producing 3-(mercapto-alkyl)-quinazoline-2,4(1h,3h)-dione derivatives and pharmaceutical preparatives containing said compounds
MXPA03010440A (es) Derivados de 4-(fenil-(piperidin-4-il)amino)-benzamida y su uso para tratamiento del dolor, ansiedad o trastornos gastrointestinales.
Mahadik et al. Contagious Disease Preventing Chamber Using Raspberry Pi
AR035878A1 (es) Antranilamidopiridinamidas selectivas, su uso para preparar un medicamento y los medicamentos que las contienen
CY2023001I2 (el) 2,4,6-τριφθορο-ν-[6-(1-μεθυλο-πιπεριδινο-4-καρβονυλο)-πυριδιν-2-υλο]-βενζαμιδιο για την αντιμετωπιση ημικρανιας μεσω της στοματικης ή της ενδοφλεβιας οδου